Aliskiren: a rapidly, expanding role in the management of recalcitrant hypertension and renal disease.
Kapoor
Shailendra
S
D000577:Amides / Q000494:pharmacology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005650:Fumarates / Q000494:pharmacology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012084:Renin-Angiotensin System / Q000187:drug effects*
D000577:Amides; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D005650:Fumarates; C446481:aliskiren